Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age

Main Article Content

Jonathan I. Silverberg
Lawrence F. Eichenfield
Adelaide A. Hebert
Eric Simpson
Linda Stein Gold
Robert Bissonnette
Kim A. Papp
John Browning
Pearl Kwong
Neil J. Korman
Philip M. Brown
David S. Rubenstein
Stephen C. Piscitelli
Matthew C. Somerville
Anna Tallman
a:1:{s:5:"en_US";s:9:"Dermavant";}

Leon Kircik

Keywords

atopic dermatitis, eczema, tapinarof cream 1% once daily, efficacy, safety, AhR agonist

References

1. Weidinger S, et al. Lancet. 2016;387:1109–1122.

2. Bieber T. N Engl J Med. 2008;358:1483–1494.

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199.

4. Lewis-Jones S. Int J Clin Pract. 2006;60:984–992.

5. Nygaard U, et al. Dermatology. 2017;233:333–343.

6. Wu JJ, et al. J Eur Acad Dermatol Venereol. 2016;30:1115–1119.

7. Menter A, et al. J Am Acad Dermatol. 2011;65:137–174.

8. Goh MS, et al. Med J Aust. 2022;216:587–9311.

9. Sideris N, et al. J Clin Med. 2022;11:4974.

10. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf. Accessed September 2023.

11. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–2229.

12. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.

13. Pepper J, et al. J Am Acad Dermatol. 2019;80:89–98.e3.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.283

Article Details

How to Cite
[1]
Silverberg, J.I., Eichenfield, L.F., Hebert, A.A., Simpson, E., Gold, L.S., Bissonnette, R., Papp, K.A., Browning, J., Kwong, P., Korman, N.J., Brown, P.M., Rubenstein, D.S., Piscitelli, S.C., Somerville, M.C., Tallman, A. and Kircik, L. 2023. Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s283. DOI:https://doi.org/10.25251/skin.7.supp.283.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>